Home/ Stocks/ MNOV

Medicinova, Inc.

MNOV XNAS

$1.34 -0.02 (-1.47%) ▼ 15-min delayed

Open

$1.36

High

$1.39

Low

$1.34

Volume

11.4K

Market Cap

$66.94M

About Medicinova, Inc.

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 6 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$187.0K	$-2,586,258	$-0.05
FY 2025	$409.7K	$-11,997,957	$-0.24
Q3 2025	$123.3K	$-3,050,373	$-0.06
Q2 2025	$134.6K	$-3,281,185	$-0.07

Related Market News

No specific coverage for MNOV yet. Check out our latest market news or earnings calendar.

Get MNOV Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Medicinova, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.